JP2011234740A - 細胞外マトリックス成分に結合する修飾タンパク質 - Google Patents
細胞外マトリックス成分に結合する修飾タンパク質 Download PDFInfo
- Publication number
- JP2011234740A JP2011234740A JP2011176306A JP2011176306A JP2011234740A JP 2011234740 A JP2011234740 A JP 2011234740A JP 2011176306 A JP2011176306 A JP 2011176306A JP 2011176306 A JP2011176306 A JP 2011176306A JP 2011234740 A JP2011234740 A JP 2011234740A
- Authority
- JP
- Japan
- Prior art keywords
- cee
- ecb
- shows
- cae
- extracellular matrix
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/745—Blood coagulation or fibrinolysis factors
- C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
- C12N2740/13022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
- C12N2740/13041—Use of virus, viral particle or viral elements as a vector
- C12N2740/13043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
- C12N2740/13041—Use of virus, viral particle or viral elements as a vector
- C12N2740/13045—Special targeting system for viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2810/00—Vectors comprising a targeting moiety
- C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
- C12N2810/80—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates
- C12N2810/85—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian
- C12N2810/857—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian from blood coagulation or fibrinolysis factors
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biomedical Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Virology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Toxicology (AREA)
- Microbiology (AREA)
- Vascular Medicine (AREA)
- Rheumatology (AREA)
- Urology & Nephrology (AREA)
- Pain & Pain Management (AREA)
- Diabetes (AREA)
Abstract
【解決手段】壁を有するプロテオリポソームであって、該プロテオリポソームの壁が細胞外マトリックス成分に結合する結合領域を含有するターゲティングポリペプチドを有する、プロテオリポソーム;およびベクター粒子を細胞外マトリックス成分へターゲティングさせる為の修飾ウイルス表面蛋白質を有するベクター粒子であって、該ウイルス表面蛋白質は細胞外マトリックス成分に結合する結合領域を含有するターゲティングポリペプチドを含むように修飾されている、ベクター粒子。
【選択図】なし
Description
Claims (1)
- 明細書中に記載の発明。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US83722397A | 1997-04-10 | 1997-04-10 | |
US08/837,223 | 1997-04-10 |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2007261428A Division JP2008031178A (ja) | 1997-04-10 | 2007-10-04 | 細胞外マトリックス成分に結合する修飾タンパク質 |
Publications (1)
Publication Number | Publication Date |
---|---|
JP2011234740A true JP2011234740A (ja) | 2011-11-24 |
Family
ID=25273860
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP54305898A Ceased JP2001523089A (ja) | 1997-04-10 | 1998-04-08 | 細胞外マトリックス成分に結合する修飾ウイルス表面蛋白質 |
JP2007261428A Withdrawn JP2008031178A (ja) | 1997-04-10 | 2007-10-04 | 細胞外マトリックス成分に結合する修飾タンパク質 |
JP2011176306A Pending JP2011234740A (ja) | 1997-04-10 | 2011-08-11 | 細胞外マトリックス成分に結合する修飾タンパク質 |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP54305898A Ceased JP2001523089A (ja) | 1997-04-10 | 1998-04-08 | 細胞外マトリックス成分に結合する修飾ウイルス表面蛋白質 |
JP2007261428A Withdrawn JP2008031178A (ja) | 1997-04-10 | 2007-10-04 | 細胞外マトリックス成分に結合する修飾タンパク質 |
Country Status (11)
Country | Link |
---|---|
US (6) | US6864082B2 (ja) |
EP (2) | EP0973538B1 (ja) |
JP (3) | JP2001523089A (ja) |
AT (1) | ATE388720T1 (ja) |
AU (1) | AU737727B2 (ja) |
CA (1) | CA2285937C (ja) |
DE (1) | DE69839243T2 (ja) |
ES (1) | ES2303726T3 (ja) |
IL (1) | IL132087A0 (ja) |
NZ (1) | NZ500006A (ja) |
WO (1) | WO1998044938A1 (ja) |
Families Citing this family (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU737727B2 (en) | 1997-04-10 | 2001-08-30 | University Of Southern California | Modified viral surface proteins for binding to extracellular matrix components |
US6387663B1 (en) * | 1998-07-31 | 2002-05-14 | University Of Southern California | Targeting pharmaceutical agents to injured tissues |
WO2001007059A1 (en) * | 1999-07-21 | 2001-02-01 | University Of Southern California | Matrix-targeted fusion polypeptides for tissue regeneration and wound healing |
US20020064520A1 (en) * | 1999-08-19 | 2002-05-30 | Yanina Rozenberg | Targeted artificial gene delivery |
NZ536851A (en) * | 1999-10-29 | 2006-05-26 | Univ Southern California | Vector particles containing TVTM peptides |
AU2001259174A1 (en) * | 2000-04-28 | 2001-11-12 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Viral and non-viral vectors as vehicles for delivering transgenes for treating bone pathologies |
HUP0300810A2 (hu) * | 2000-07-20 | 2003-08-28 | M.G.V.S. Ltd. | Mesterséges értranszplantátum, valamint ennek létrehozása és alkalmazása |
US7175658B1 (en) | 2000-07-20 | 2007-02-13 | Multi-Gene Vascular Systems Ltd. | Artificial vascular grafts, their construction and use |
ES2186501B1 (es) * | 2000-11-23 | 2006-05-16 | Universidad De Malaga | Factor de crecimiento fibroblastico basico con un dominio de union especifico a colegeno. |
WO2002044394A2 (en) | 2000-11-29 | 2002-06-06 | University Of Southern California | Targetet retoviral vectors for cancer immunotherapy |
WO2003087329A2 (en) * | 2002-04-11 | 2003-10-23 | University Of Southern California | Targeted cytocidal virionoids for antiangiogenesis |
US20090123428A1 (en) * | 2003-04-21 | 2009-05-14 | Hall Frederick L | Pathotropic targeted gene delivery system for cancer and other disorders |
JP2006524057A (ja) | 2003-04-21 | 2006-10-26 | エペイウス バイオテクノロジーズ, インコーポレイテッド | 疾患を処置するための方法および組成物 |
US20070178066A1 (en) | 2003-04-21 | 2007-08-02 | Hall Frederick L | Pathotropic targeted gene delivery system for cancer and other disorders |
WO2007095201A2 (en) * | 2006-02-15 | 2007-08-23 | The Regents Of The University Of California | Pseudotyped retroviral vectors and methods of use thereof |
EP2654793B1 (en) | 2010-12-21 | 2017-09-13 | Leidos, Inc. | Methods and compositions for wound treatment |
WO2012112690A2 (en) * | 2011-02-16 | 2012-08-23 | Fabius Biotechnology | Targeting of therapeutic drugs and diagnostic agents employing collagen binding domains |
ES2703341T3 (es) | 2013-03-14 | 2019-03-08 | Genvivo Inc | Ensayo diagnóstico de timidina quinasa para aplicaciones de terapia génica |
EP3377637B1 (en) | 2016-04-08 | 2020-03-18 | Krystal Biotech, LLC | Compositions for use in methods for the treatment of wounds, disorders, and diseases of the skin |
WO2019200163A1 (en) | 2018-04-12 | 2019-10-17 | Krystal Biotech, Inc. | Compositions and methods for the treatment of autosomal recessive congenital ichthyosis |
EP3810149A4 (en) | 2018-04-27 | 2022-08-24 | Krystal Biotech, Inc. | RECOMBINANT NUCLEIC ACIDS ENCODING COSMETIC PROTEINS FOR AESTHETIC APPLICATIONS |
WO2020068862A1 (en) | 2018-09-24 | 2020-04-02 | Krystal Biotech, Inc. | Compositions and methods for the treatment of netherton syndrome |
CA3127133A1 (en) | 2019-02-08 | 2020-08-13 | Krystal Biotech, Inc. | Compositions and methods for delivering cftr polypeptides |
WO2022212896A1 (en) | 2021-04-02 | 2022-10-06 | Krystal Biotech, Inc. | Viral vectors for cancer therapy |
Family Cites Families (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5591624A (en) * | 1988-03-21 | 1997-01-07 | Chiron Viagene, Inc. | Retroviral packaging cell lines |
WO1989009271A1 (en) * | 1988-03-21 | 1989-10-05 | Viagene, Inc. | Recombinant retroviruses |
US5328470A (en) * | 1989-03-31 | 1994-07-12 | The Regents Of The University Of Michigan | Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor |
US5672510A (en) | 1990-01-19 | 1997-09-30 | Genetic Therapy, Inc. | Retroviral vectors |
EP0511311A4 (en) | 1990-01-19 | 1993-05-26 | United States Government As Represented By The Secretary Of The Department Of Health And Human Services | Novel retroviral vectors |
AU660629B2 (en) | 1990-10-01 | 1995-07-06 | University Of Connecticut, The | Targeting viruses and cells for selective internalization by cells |
ATE169061T1 (de) * | 1990-10-25 | 1998-08-15 | Clague Pitman Hodgson | Methode des gentransfers mittels retrotransposons |
US5512421A (en) * | 1991-02-19 | 1996-04-30 | The Regents Of The University Of California | Generation, concentration and efficient transfer of VSV-G pseudotyped retroviral vectors |
WO1993000103A1 (en) | 1991-06-21 | 1993-01-07 | The Wistar Institute Of Anatomy And Biology | Chimeric envelope proteins for viral targeting |
SE503225C2 (sv) | 1991-10-30 | 1996-04-22 | Leif Lindholm Konsult Ab | Virus-antikroppskomplex för införing av virus i mammalieceller |
WO1993014188A1 (en) | 1992-01-17 | 1993-07-22 | The Regents Of The University Of Michigan | Targeted virus |
WO1993020221A1 (en) | 1992-04-03 | 1993-10-14 | Young Alexander T | Gene therapy using targeted viral vectors |
JPH07507689A (ja) | 1992-06-08 | 1995-08-31 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 特定組織のターゲティング方法及び組成物 |
US5821234A (en) | 1992-09-10 | 1998-10-13 | The Board Of Trustees Of The Leland Stanford Junior University | Inhibition of proliferation of vascular smooth muscle cell |
WO1994006921A1 (en) | 1992-09-21 | 1994-03-31 | Viagene, Inc. | Recombinant retroviral vector against felv and/or fiv |
CA2145063A1 (en) * | 1992-09-22 | 1994-03-31 | Cambridge Genetics Limited | Recombinant viruses displaying a nonviral polypeptide on their external surface |
GB9223084D0 (en) | 1992-11-04 | 1992-12-16 | Imp Cancer Res Tech | Compounds to target cells |
JP3533219B2 (ja) | 1992-11-09 | 2004-05-31 | アメリカ合衆国 | 標的指向ベクター粒子 |
JPH08504098A (ja) | 1992-11-20 | 1996-05-07 | ユニバーシティー オブ メディスン アンド デンティストリー オブ ニュー ジャージー | 抗体−エンベロープ融合蛋白を含有するレトロウィルスベクターを用いた細胞種特異的な遺伝子転移 |
WO1994019478A1 (en) | 1993-02-22 | 1994-09-01 | The Rockefeller University | Production of high titer helper-free retroviruses by transient transfection |
WO1994027643A1 (en) | 1993-06-01 | 1994-12-08 | Targeted Genetics Corporation | Envelope fusion vectors for use in gene delivery |
WO1995003402A1 (en) * | 1993-07-22 | 1995-02-02 | Merck & Co., Inc. | EXPRESSION OF HUMAN INTERLEUKIN-1β IN A TRANSGENIC ANIMAL |
US5543328A (en) | 1993-08-13 | 1996-08-06 | Genetic Therapy, Inc. | Adenoviruses having modified fiber proteins |
EP0723595A1 (en) | 1993-10-22 | 1996-07-31 | The Board Of Regents, The University Of Texas System | A novel nuclear mitotic phosphoprotein: mitosin |
US5643770A (en) * | 1994-07-21 | 1997-07-01 | Alexion Pharmaceuticals, Inc. | Retroviral vector particles expressing complement inhibitor activity |
US5681746A (en) | 1994-12-30 | 1997-10-28 | Chiron Viagene, Inc. | Retroviral delivery of full length factor VIII |
AU716056B2 (en) | 1995-01-31 | 2000-02-17 | Rockefeller University, The | Identification of DEC, (dentritic and epithelial cells, 205 kDa), a receptor with C-type lectin domains, nucleic acids encoding DEC, and uses thereof |
AU5320296A (en) * | 1995-03-24 | 1996-10-16 | Genetic Therapy, Inc. | Modified viral envelope polypeptide |
GB9506782D0 (en) * | 1995-04-01 | 1995-05-24 | British Biotech Pharm | Retroviral vectors |
US5800811A (en) | 1995-06-06 | 1998-09-01 | Hall; Frederick L. | Artificial skin prepared from coclagen matrix containing transforming growth factor-β having a collagen binding site |
AU737727B2 (en) * | 1997-04-10 | 2001-08-30 | University Of Southern California | Modified viral surface proteins for binding to extracellular matrix components |
US6004798A (en) | 1997-05-14 | 1999-12-21 | University Of Southern California | Retroviral envelopes having modified hypervariable polyproline regions |
US20020173538A1 (en) | 2000-06-30 | 2002-11-21 | Ming-Shi Shiao | Method for sensitizing cancer cells to cancer therapies with a mevalonate-reducing compound |
EP1360311B1 (en) | 2000-08-25 | 2008-04-09 | Aventis Pharmaceuticals Inc. | Membrane penetrating peptides and uses thereof |
-
1998
- 1998-04-08 AU AU68903/98A patent/AU737727B2/en not_active Expired
- 1998-04-08 CA CA2285937A patent/CA2285937C/en not_active Expired - Lifetime
- 1998-04-08 DE DE69839243T patent/DE69839243T2/de not_active Expired - Lifetime
- 1998-04-08 AT AT98914585T patent/ATE388720T1/de not_active IP Right Cessation
- 1998-04-08 WO PCT/US1998/006936 patent/WO1998044938A1/en active IP Right Grant
- 1998-04-08 EP EP98914585A patent/EP0973538B1/en not_active Expired - Lifetime
- 1998-04-08 ES ES98914585T patent/ES2303726T3/es not_active Expired - Lifetime
- 1998-04-08 EP EP08004101A patent/EP2008664B1/en not_active Expired - Lifetime
- 1998-04-08 IL IL13208798A patent/IL132087A0/xx not_active IP Right Cessation
- 1998-04-08 NZ NZ500006A patent/NZ500006A/en not_active IP Right Cessation
- 1998-04-08 JP JP54305898A patent/JP2001523089A/ja not_active Ceased
-
2001
- 2001-07-13 US US09/904,923 patent/US6864082B2/en not_active Expired - Fee Related
-
2004
- 2004-12-15 US US11/014,629 patent/US7347998B2/en not_active Expired - Fee Related
-
2007
- 2007-10-04 JP JP2007261428A patent/JP2008031178A/ja not_active Withdrawn
-
2008
- 2008-01-18 US US12/016,847 patent/US7820157B2/en not_active Expired - Fee Related
-
2010
- 2010-09-10 US US12/879,511 patent/US8148509B2/en not_active Expired - Fee Related
-
2011
- 2011-08-11 JP JP2011176306A patent/JP2011234740A/ja active Pending
-
2012
- 2012-03-29 US US13/433,615 patent/US8530441B2/en not_active Expired - Fee Related
-
2013
- 2013-08-05 US US13/959,570 patent/US8871734B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
US20120276052A1 (en) | 2012-11-01 |
NZ500006A (en) | 2001-09-28 |
WO1998044938A1 (en) | 1998-10-15 |
US20130331547A1 (en) | 2013-12-12 |
US8530441B2 (en) | 2013-09-10 |
US20110065179A1 (en) | 2011-03-17 |
CA2285937C (en) | 2010-12-14 |
ES2303726T3 (es) | 2008-08-16 |
EP0973538A1 (en) | 2000-01-26 |
EP0973538B1 (en) | 2008-03-12 |
US20030118551A1 (en) | 2003-06-26 |
US20050244376A1 (en) | 2005-11-03 |
US8871734B2 (en) | 2014-10-28 |
US20080241905A1 (en) | 2008-10-02 |
US6864082B2 (en) | 2005-03-08 |
JP2001523089A (ja) | 2001-11-20 |
ATE388720T1 (de) | 2008-03-15 |
EP0973538A4 (en) | 2001-09-19 |
US8148509B2 (en) | 2012-04-03 |
US7820157B2 (en) | 2010-10-26 |
AU6890398A (en) | 1998-10-30 |
CA2285937A1 (en) | 1998-10-15 |
DE69839243D1 (de) | 2008-04-24 |
EP2008664B1 (en) | 2012-08-29 |
JP2008031178A (ja) | 2008-02-14 |
EP2008664A2 (en) | 2008-12-31 |
EP2008664A3 (en) | 2009-03-11 |
AU737727B2 (en) | 2001-08-30 |
DE69839243T2 (de) | 2009-04-30 |
US7347998B2 (en) | 2008-03-25 |
IL132087A0 (en) | 2001-03-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2011234740A (ja) | 細胞外マトリックス成分に結合する修飾タンパク質 | |
Pollok et al. | High-efficiency gene transfer into normal and adenosine deaminase-deficient T lymphocytes is mediated by transduction on recombinant fibronectin fragments | |
Khani et al. | AAV-mediated expression targeting of rod and cone photoreceptors with a human rhodopsin kinase promoter | |
Takeuchi et al. | Sensitization of cells and retroviruses to human serum by (αl-3) galactosyltransferase | |
Hildinger et al. | Design of 5′ untranslated sequences in retroviral vectors developed for medical use | |
US6485965B1 (en) | Replicating or semi-replicating viral constructs, preparation and uses for gene delivery | |
Corboy et al. | Expression directed from HIV long terminal repeats in the central nervous system of transgenic mice | |
EP1104482B1 (en) | Cell type specific gene transfer using retroviral vectors containing antibody-envelope fusion proteins and wild-type envelope fusion proteins | |
US20080008685A1 (en) | Viral vectors | |
AU9356298A (en) | Expression of genes in hematopoietic stem cells in hischaemic conditions | |
JPH08504098A (ja) | 抗体−エンベロープ融合蛋白を含有するレトロウィルスベクターを用いた細胞種特異的な遺伝子転移 | |
WO1995023846A1 (en) | Cell-type specific gene transfer using retroviral vectors containing antibody-envelope and wild-type envelope-fusion proteins | |
JP3923078B2 (ja) | あらかじめ定まった結合価を持つアダプターを有するウイルスベクター複合体 | |
US7608449B2 (en) | Methods and compositions related to high-titer pseudotyped retroviruses | |
JP2000157289A (ja) | 平滑筋細胞および/または内皮細胞への組織向性を与えられた遺伝子送達ベクタ― | |
EP1059356B1 (en) | Replicating retroviral constructs, preparation and uses for gene delivery | |
US7261885B2 (en) | Adenoviral vector with replication-dependent transgene expression | |
CA2077686A1 (en) | Binary genetic system to control expression of a transgene in a transgenic animal | |
CA2250183A1 (en) | Psa positive regulating (psar) sequences and uses thereof | |
March | Gene transfer in the cardiovascular system: experimental approaches and therapeutic implications | |
US20050106125A1 (en) | Use of AAV integration efficiency element for mediating site-specific integration of a transcription unit | |
Smith-Arica | Cell-type specific and regulated transgene expression from first generation recombinant adenoviral vectors: Characterisation in vitro and in vivo | |
Trapnell et al. | Development of viral vectors for human gene therapy: retrovirus and adenovirus (Part I) | |
Duarte | 77. HIV-1 Vector Production Mediated by Rev Protein Transduction | |
JP2004535151A6 (ja) | ウイルス性成分の活性および/または特異性の評価に対する新システム |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20110811 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20120619 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20130110 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20130408 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20130514 |
|
RD02 | Notification of acceptance of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7422 Effective date: 20130514 |
|
RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20130516 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20130514 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20140120 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20140702 |